OncLive TV

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Michael J. Cavnar, MD, discusses ​surgical differences between right- and left-sided tumors in colorectal cancer.

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Prakash Pandalai, MD, ​discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.

Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Lan G. Coffman, MD, PhD, discusses the role of targeted therapy in triple-negative breast cancer.

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.

Hussein A. Tawbi, MD, PhD, discusses future research efforts in melanoma.

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

Ursula A. Matulonis, MD, discusses the need to improve responses to immunotherapy among patients with recurrent gynecologic cancers.

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

Christian Buske, MD, discusses ​the results of the iNNOVATE trial in Waldenström macroglobulinemia.

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.